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ABSTRACT  
This paper focuses on the synthesis of novel metal-drugs nanoparticles based onto gold-
gemcitabine complexes relevant for biomedical applications. Gold (HAuCl4) are mixed with 
antitumor compounds (gemcitabine (GEM)) and dicarboxylic acid-terminated polyethylene-
glycol (PEG) that plays a double role as surfactants and reducing agent. The proposed 
methodology is fast and reproducible and leads the formation of   hybrid-metal nanoflowers  
called GEM ION-PEG-AuNPs, in which drug solubility and efficiency were improved. For 
therapeutic purposes, we introduce the emerging roles of GEM ION-PEG-AuNPs in the 
hyperthermic treatment of cancer throught preliminary study based of temperature effect onto 
colloidal solutions under specific experimental conditions. For this purpose GEM ION-PEG-
AuNPs were decorated with HIV-1 Tat peptide that is a potent trans-activator of transcription 
from the viral promoter and is essential for viral replication containing an activation domain 
and a nucleic acid-binding domain. . All product were evaluated   by various spectroscopic 
techniques (Raman and UV-Vis spectroscopies) and transmission electron microscopy (TEM). 
This study, mean an original chemical approach, will employ an important position in the 
field of Nanomedicine, with novel perspectives that will be proposed for the development of 
news drugs and active targeting in cancer therapy. 
KEYWORDS: AuNPs, Gemcitabine, HIV-1 Tat peptide, Raman Spectroscopy, gold 
complex, nanovector, hyperthermie. 
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1. Introduction  
In the recent years, nanotechnologies applied to Medicine (e.g. Nanomedicine) have led to 
propose engineered tunable devices with the size of the order of nanometers as an intriguing 
tool potentially able to solve unmet problems in healthcare 
[1]
. Smart nanomaterials and 
advanced nanotechnologies required the rapid development of original protocols for 
biomedical applications 
[2]
. Among them, Gold Nanovectors are fascinating remarkable 
interest as workable biomedical materials and the research effort about this subject is 
continuously growing, due to their unique physical and biochemical properties 
[3]
. The 
utilization of biomolecules and/or biopolymer-grafted AuNPs are widely used as biomarkers 
in cancer early detection and as in vivo drugs delivery systems in medicine/pharmacy 
applications, and also in beauty products 
[4]
. 
Nanocarrier-based drug delivery systems afford key advantages to the conventional treatment 
modes: controlled release and targeted delivery. The ability to keep the drug inactive, while in 
transit, and release it in its active form, under the appropriate physiochemical conditions 
[5]
, 
mitigates the collateral damage to healthy tissue, which in conventional approaches is an 
inherent consequence that goes largely unchecked. Additionally, through multifunc-
tionalization, nanocarriers can contain not only anticancer payloads but also ligands that 
preferentially bind to surface receptor proteins of cancer cells and mediate endocytosis of the 
nanocarrier. Recently, J.Spadavecchia et al. have developed  original nanovectors  based on 
drugs-gold-complex (i.e. doxorubicin, docetaxel, paclitaxel), according to a chelation 
methodology in which the drug was complex with tetrachloauric acid (HAuCl4) and polymer 
molecules (PEG diacide) before reduction to final nanovector
[2c, 6]
. Chemical-physical 
characterizations and biological studies of drugs-gold-complex, have showed a remarkable 
interest in its therapeutic activity to in vitro model of Pancreatic Ductal Adeno Carcinoma 
(PDAC) 
[2c, 4]
. Other authors have studied the mechanism of hybrid nanoparticles using 
biocompatibles polymers as capping agent 
[7]
. Behind anticancer drugs of interest, 
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Gemcitabine  is a cytosine analogue   (Scheme S1 Supporting Informations) that  represent 
an antineoplastic agent used in the therapy of several forms of advanced, pancreatic, lung, 
breast, ovarian and bladder cancer
[8]
 . A serious limitation of the drug is its in vivo half-life of 
~20 min, resulting from deamination by deoxycytidilate deaminase 
[9]
. 
In order to checked the release of GEM, several nanocarriers were carried out under specific 
conditions of the synthesis and surface functionalization 
[10]
 
[9]
. Many authors have been used 
micelles and metal (Au, Ag, or Cu) to grafted GEM as nanocarrier 
[8c]
 
[10]
. Others authors, 
have been grafted GEM on the NPs through  a self-assembled monolayer (SAM) of functional 
thiols and  folic acid (FA) or transferrin (TF) can improve  targeted controlled-release of the 
drug, reducing the side effects of the drug and improving efficacy 
[11]
. During the last decade 
several cell penetrating peptides, such as the HIV-1 tat peptide, have been shown to traverse 
the cell membrane, where integral protein transduction domains (PTDs) are responsible for 
their cellular uptake, and to reach the nucleus while retaining biological activity
[12]
. It has 
since been discovered that PTDs can enable the cellular delivery of conjugated biomolecules 
and even nanoparticles, but nuclear delivery has remained problematic
[12]
.  This study 
provides , for the first time, the basis for the development of a stable and biocompatible 
gemcitabine gold nanovector like flower-shape, conjugated with the HIV-1 Tat PTD with the 
objectif, to generate nuclear anticancer targeting agents . The particles were successively 
assayed in vitro with pancreatic adenocarcinoma PDAC cell line (PANC-1), in order to 
understand the bio-chemical behavior of peptide-gold nanovector after cell internalization. 
The therapeutic design introduced in this paper represent a novel approach to enhance the 
efficacy of gemcitabine, with the utilization of an active peptide targeting delivery system, 
employed as thermosensitive hybrid gold nanocarriers and prospective anticancer  in 
nanomedicine field for direct targeting of tumour cells using peptide-conjugated gold NPs 
with gemcitabine as anticancer drug.  
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2.RESULTS AND DISCUSSION 
Formation mechanism of GEM ION-PEG-AuNPs  
Recently, J.Spadavecchia et al. have designed some new nano-therapeutics agent based on 
drugs-gold-complex (i.e.doxorubicin, docetaxel, paclitaxel), according to a methodology 
named “Method IN”, in which the drug was complex with tetrachloauric acid (HAuCl4) 
before nanoparticle formation in presence of biocompatible polymer molecules (PEG diacide) 
as surfactant, and NaBH4 as reducing agent. Chemical-physical characterizations and 
biological “in vitro” studies of drugs-gold-complex, have successfully showed a large 
influence in its therapeutic activity 
[4a, 13]
 . Other authors have studied the mechanism of 
hybrid nanoparticles and competition effect with different capping agent on the growth 
process
[2a, 14]
. In this case we develop a modification of “Method IN”, in which, the main 
difference with previously reported synthetic procedures is that GEM participate to the 
stabilization of AuNPs via complexation and electrostatic interaction between your chetone 
and amino groups with chloride auric ions and dicarboxylic pegylated chaines.  
In particular, the formation of gold NPs from AuCl4
-
 includes some mains steps (scheme 1): 
(1) Complexation and initial reduction of AuCl4
-
 ions by dicarboxylic acid-terminated 
PEG that adsorbs onto Au surface and generation of peg-gold clusters 
 (2) Electrostatic Adsorption of Gemcitabine onto PEG-Au-complex 
 (3) Reduction of metal ions in that vicinity and growth of gold particles and colloidal 
stabilization by molecules of PEG polymers. 
In the first step, dicarboxylic PEG was added in HAuCl4 aqueous solution to complex with 
him as described previously
[4b]
. The addition of PEG-COOH increases the reduction process 
by complexation of Au ions, thought carboxylic groups, controlling the initial growth  of 
nanoparticles
[2a]
 . Finally, the reduction by NaBH4, complete the reduction process of final 
nanoparticles (third step). When GEM molecules were mixed with PEG-Au solution, the 
charged residues opposite to the skeletal of  GEM ( preferentially –NH3
+
) were thought to 
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interact with the polar surface of PEG chaines  in such a way as the conformation structure of 
drug   was turned of the gold surface (see scheme 1). This steric arrangement of GEM in 
PEG-Au clusters before reduction of HAuCl4 during synthetic process of gold nanoparticles, 
was confirmed by UV-Vis absorption spectroscopy, TEM and Raman Spectroscopy reported 
in the following. 
 
Comparative physico-chemical characterization of GEM ION-PEG-AuNPs: 
Gemcitabine (2'-deoxy-2',2'- difluorocytidine ; GEM) is antimetabolite and deoxycytidine 
analogue (Scheme S1 in the Supporting Informations) that has been used as a 
chemiotherapeutic agent with antineoplastic activity for last two decades
[15]
 . In particular, 
GEM shows a hydroxyl and chetone functional group responsible of  anticancer activity
[16]
. 
Physicochemical properties of GEM do not allow for electrostatic interaction with all 
nanoparticle surface. For this reason, in previous studies, GEM was grafted onto iron-oxide 
nanoparticles by cicloaddition through Diels Alder reaction 
[10]
.  
In our study, GEM was electrostatically grafted onto pegylated complex to the AuCl4
-
 
solution, in order to form metallo-nanoflowers. TEM images of GEM ION-PEG-AuNPs 
display a snow-like shape, embedded in a shell of PEG, with a similar diameter around 50 ± 2 
nm (Figure 1-B), compared with PEG-AuNPs as control
[4b]
 with an average size of 7.5 ± 1nm 
(Figure 1-A). J.Spadavecchia et al. have reported the synthesis of similar nanostructures 
using dicarboxylic PEG 
[2c, 4a, 13b]
 and drugs, while characteristic snowflakes nanoparticles 
were obtained by incorporating protoporphyrin molecules in the growth solution of AuNPs 
[17]
 . On the basis of previous studies
[2a, 13b, 14]
 we presume that, when GEM was added to 
complex PEG-AuCl4
-
, the PEG  change your chemical conformation switching from 
mushroom to brush mode conformation. The absorption spectra of GEM ION-PEG-AuNPs 
and PEG AuNPs were characterized by a small peak at 300 nm, assigned to the PEG 
absorption, and a surface plasmon band at 535 nm (Figure 1-C red line) for PEG-AuNPs and 
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608 nm for GEM ION-PEG-AuNPs (Figure 1-C blue line) respectively. PEG-COOH, as 
stabilizing polymers, provides to the formation of coordination bands between the Au ions 
and the chetone or amino groups of GEM with a good dispersion of the Au ions, and 
consequently growth of AuNPs like flowers. This behaviour is associated to π-π* electronic 
transitions due to interactions between the pyrimidine ring and PEG-AuCl4
- 
ions. 
The loading of GEM on the gold nanoparticles was confirmed by the presence of the peak at 
270 nm, and the strong decrease of the band at 608 nm with consequently disappearance of 
the band at 300 nm in the UV-Visible spectra (Figure 1-C blue line) and the tendency of 
snow-like shape to agglomerate differently. This chemical behavior, is due to a different 
adsorption onto gold facets [110] of GEM, based on their different steric conformation of 
chemical groups (Scheme S1) during nucleation and growth process of AuNPs. In addition 
the color bright violet-blue of the obtained nanoparticles and the UV-Vis spectra remain 
unalterated after storage for more than six months at room temperature suggesting the 
formation of stable particle suspension. The chemical ad steric arrangement of GEM onto 
pegylated gold nanoparticles was confirmed by Raman spectroscopic analysis (Figure 1-D). 
T.Y Santiago et al. have synthetized and characterized GEM-gold nanoparticles by Raman 
spectroscopy
[11]
.These authors, have immobilized GEM on the gold nanoparticle (AuNP) 
throught covalently bonded thiol linkers and  spectroscopic analysis showed  that the specific 
functional groups of the GEM-AuNPs were chemically modified before the grafting of 
AuNPs. Contrary to this study, we have involved other ingredients (drug, polymer) chelated 
to gold ions, to form gold nanoparticles, in which the spectroscopical fingerprints of our final 
nano-drug are peculiar compared to the free drugs.  
 
In detail, Raman spectra of free GEM  and GEM ION-PEG-AuNPs  in water exhibit many 
bands in the region 500-2000 cm
-1 
(The wide band observed around 1600 cm
-1
 on the GEM 
ION-PEG-AuNPs Raman spectra is assigned to the water) (Figure 1-D). In particular, the 
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peak at 823 cm
-1
 characteristic of the aromatic proton and C-F groups, the vibrations at 1250 
cm
-1
 and 1300 cm
-1
 due to ν C-O-C stretching and the vibration at 1655 cm-1 due to 
protonated NH2. We observed an exaltation of the peak at at 430 cm
-1
 due to the C-N 
vibrations of the pyperazynil group. In addition, we note the disappearance of a band present 
in the spectrum of "free" Gemcitabine located between 469 and 514 cm
-1
 when the GEM is 
grafted on gold nanospheres due to the C-C-O vibration. The prominent peak at 430 cm
-1
 is 
due to the vibrations δ(OH…O), ν(OH…O) of the PEG. Based on the spectrochemical and 
previously theoretical results, we assumed that Au
3+
 ions promoted the deprotonation of the 
GEM ciclopenthanol group at position C-5’. We have also observed that more peaks were 
exalted in the region between 1000 cm
-1
 and 1200 cm
-1
 due to a chemical and steric 
arrangement of GEM onto pegylalated gold nanoparticles previous complexation as described 
previously
[13a]
.  
Drug loading and release of GEMION-PEG-AuNPs:  
Recently, A.Oluwasanni et al. have studied the process of loading of GEM onto hybrid iron 
oxide-nanoparticles (HNPs) by Diels Alder reaction
[10]
.This formulation was capable of high 
drug loading (86%) which appeared stable even upon reduction of pH and provided to a rapid 
liberation of the prodrug at elevated temperatures, throught retro Diels Alder breakdown 
[10, 18]
. 
Previously Lele Li et al. have  obtained a drug loading of about 55% after self-assembled of 
GEM onto Diphosphate-PEG based gadolinium nanoparticles (GdNPs)
[18]
. In similar case, 
other authors have immobilized GEM on the nanoparticle (NP) through a pH-sensitive amide 
bond. This bond prevents the drug from being metabolized or acting on tissue at physiological 
pH 7.4, but breaks, releasing the drug at acidic pH, characteristic of cancer cells
[11]
. In our 
case, after complexation of AuCl4
-
 with PEG diacid chaines, GEM was binding 
electrostatically onto complex before reduction of NaBH4 to obtain GEM ION-PEG-AuNPs. 
In this novel formulation GEM assume a different chemical and sterical conformation 
compared to recent synthesis approach in which the drug molecules reside inside the AuNP 
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core
[6a, 13b]
. The successful loading ratio of GEM onto PEG-AuNPs, were evidenced by the 
characteristic absorption peaks at 268 nm from GEM (Figure S2 Supporting information). 
The standard absorption of GEM was plotted in the inset of figure (Figure S2 supporting 
information) according to UV-Vis absorbance spectra of GEM at various concentrations. The 
loading efficiencies were estimated to be 86% with 8.5 µg present in 2.5×10
-8
 mol of NPs 
(data not shown). GEM releases were pH- and time-dependent (Figure 2 A-B). A sustained 
drug release was observed in the first 5 h for both drugs at pH 4 and 7, which is highly 
favorable for drug delivery as the cancer cells thrive in acidic conditions. We presumed that 
the release of GEM was checked by a ionic equilibrium between Au (III)-PEG complexes 
trapped into AuNPs by the hydrophobic interactions between PEG chaines and ionic drug. As 
previously described, the mechanism by which acidic pH triggers drug release is probably 
associated to the presence of carboxylate groups in the chemical structure of PEG molecules. 
Such groups become protonated at acidic pH. This reduces the electrostatic interactions 
occurring between PEG and drugs that stabilize the GEM ION-PEG-AuNPs  structure.  
 
We suppose that, the ionic strength and protonation of GEM onto PEG chains improve the 
water solubility of the drug molecules, taking advantage of the drug release from AuNPs. 
Indeed, a remarkable moiety of GEM electrostatically binding onto dissociated complex is 
released, through PEG chain and diffusion phenomena 
[2c, 19]
. 
 
Stability under pH and electrolytic conditions. 
In order to understand the behavior of GEM ION PEG-AuNPs and HIV-1 Tat GEM ION 
PEG-AuNPs as future diagnostic or drug delivery tools, comparative studies of nanoparticles 
exposed to different pH solution under ionic strength were carried out. Localized Surface 
Plasmon (LSP) band at 565 nm (was performed under different pH and ionic strength  
conditions over a reasonable period of time (3 months). The synthesized GEM ION PEG-
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AuNPs did show an almost negligible change in the LSP band position over a period of three 
months at the pH 5 and pH 7 (Figure S1 in  Supporting Information). As described 
previously
[20]
,  the stability of AuNPs at lower concentrations is crucial, in biomedical 
applications because chemical and photophysical properties were preserved  under in vitro 
and in vivo environments
[21]
. A change of around 1nm in λmax was reputed, relevant to assess 
AuNPs stable over that period of time in a particular medium. As described previously,  after 
cell internalization , Na+ and Cl- ions were applied  to  change the concentration of  other 
compounds, by affecting in the direction in which water diffuses to form macromolecules in 
the human body 
[22]
. Other authors , have showed that pegylated nanoparticles functionalized 
with amount 16.8 and 25.2 μg/ml of PEG, remain stable in 1M NaCl which is a value well in 
excess of the normal physiological salt concentration (0.15 M)
[23]
. In our case, GEM ION 
PEG-AuNPs and HIV-1 Tat GEM ION PEG-AuNPs preserve your morphology and size 
under ionic strength conditions (2 M NaCl) as showed in Figure 3 A. A change in the LSP 
band position was negligible for few amount of NaCl and decrease dramatically at high dose 
rates. TEM Images (Figure 3 B) revealed a good homogeneity and stability due probably to a 
good equilibrium between ionic species (Na
+
 Cl
-
), polymer chains (PEG-COOH), 
Gemcitabine (GEM) and Peptide ( HIV-1 TAT).  
 
Peptide Active Targeting 
Drug-gold nanoparticles (GEM IN PEG-AuNPs) was used as a support for the conjugation of 
HIV-1 Tat   targeting moiety. HIV-1 Tat peptide is a strong trans-activator of transcription 
and play a key role during   viral replication 
[24]
. The structure of the Tat peptide be alike a 
peculiar transcriptional activator including an activation domain and a nucleic acid-binding 
domain. HIV-1 Tat molecules were immobilized on the surface of activated nanoparticles 
through the formation of amide links between the COOH groups decorating the surface of the 
drug-gold nanoparticles and the NH2 groups of the peptide (Scheme 2). 
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The binding between HIV-1 Tat protein and GEM-gold nanoparticles were monitored by 
detecting changes in the LSP band (Figure 4A). GEM ION PEG-AuNPs showed an LSP 
band centered at ~608 nm, typical of AuNPs 
[25]
. After immobilization of anti HIV-1 Tat 
protein onto GEM ION PEG-AuNPs, the resulting solution was colorless and was 
characterized by a broad LSP peak at 630 nm, which could be assigned to a change of 
localized refractive index of PEG-AuNPs and to the formation of NP agglomeration. Based on 
the UV–Vis spectra, we suggest that the significant red shift and broadening of the LSP band 
in the UV-Vis spectra could be associated to the successful bioconjugation of the AuNPs 
surface with anti HIV-1 Tat protein and the subsequent AuNPs agglomeration associated to 
the formation of classical van der Waals inter-peptide interaction
[26]
. Hypothesizing that the 
size of the HIV-1 Tat protein   is about 20 nm 
[27]
, we can estimate that the peptide stabilised 
the inter-particle distance via a double combination of electrostatic and steric repulsions 
among the various proteins linked to the PEG-chain grafted onto the nanoparticles’ surface. 
This phenomenon was confirmed by TEM images analysis (Figure 4 B) by means of which 
the size of gold-nanoflowers of about 60 nm, as well as the presence of agglomerates, was 
evaluated. In particular, it was observed that HIV-1 Tat GEM ION PEG-AuNPs were 
uniformly dispersed, confirming that the amphiphilic HIV-1 Tat GEM ION PEG layer grafted 
to the gold core of the nanoflowers stabilized the colloidal suspension. High-Resolution TEM 
(HR-TEM) image (Figure 4 B), of HIV-1 Tat GEM ION PEG-AuNPs clearly display the 
presence of an organic PEG layer of few nanometers among two gold nanoflowers throught   
inter-peptide interaction .The achievement of peptide grafting and the covalent conjugation 
via EDC/NHS groups, were also confirmed by Raman spectroscopy (Figure 4 C). SERS 
effect can be observed. An enhancement of certains peaks corresponding to the C-S stretch 
(674 cm
-1
 ; 692 cm
-1
; 745 cm
-1) provides  some informations about peptide’s 
backbone
[28]
.This is confirmed by the broadening of the peak , confirming  a higher number of 
peptide conformations inside the PEG layer (higher porosity or lower charges) after GEM IN 
PEG-AuNPs binding
[26, 29]
. 
 
 
The NP sizes were confirmed by DLS measurements (Table 1). Zeta potential measurements 
show that GEM ION-PEG-AuNPs and HIV TAT-1 GEM ION-PEG-AuNPs were colloidally 
stable at physiological pH (z-potential = -25±2 Mv and -30 ±1 mV with a PdI equal to 0.3). 
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Table 1:  z-potential and hydrodynamic diameter of GEM ION PEG-AuNPs   and HIV-1 Tat 
GEM ION PEG-AuNPs 
 
Synthetic product 
 
Zeta potential 
(mV) 
Hydrodynamic 
diameter 
(nm) 
PdI 
GEM ION PEG-
AuNPs 
 -25 ± 2 50 ± 2 0.3 
HIV-1 Tat GEM ION 
PEG-AuNPs 
 
-30 ± 1 63± 2 0.3 
 
  
 
Efficacy: 
During the interaction between GEM and DNA, a single deoxynucleotide is incorporated and 
breaking off  the   chain elongation [19]. The non-terminal position of gemcitabine promote 
DNA polymerases , and inhibits removal of gemcitabine by exonucleases 
[30]
. Biological 
studies were performed to assess the targeting efficacy of HIV Tat-1 peptide and the 
functional activity of gemcitabine in the nanoconjugated form (GEM ION PEG AuNPS) 
against various PDAC (PANC-1) cell lines in vitro.  
Tat peptide have been reported to translocate through the cell membrane and to carry 
exogeneous molecules into cytoplasma and nucleus
[31]
. HIV Tat-1 is an 86 amino-acid protein 
and aa 47-57 of Tat possess a high net negative charge at physiological pH, with nine of its 11 
aminoacids being either arginine or lysine. Fusion of several proteins and this 11 aa region of 
Tat protein enables the delivery of proteins into cells. Thus, this 11aa region is considered a 
protein transduction domain (PTD)
[31-32]
. Previously, H. Hashida et al , have studied 
molecular conjugates of poly-lysine with natural or artificial ligands using the DNA-binding 
and condensing properties of poly-lysine to mediate interaction with DNA 
[31]
. Upon 
formation of DNA-polylysine ligand complex (polyplex)
[33]
, gene transfer is facilitated via 
receptor-mediated endocytosis. In our study, we investigated, for the first time, the potential 
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role of GEM onto pegylated gold complex fused Tat-1 PTD as a gene delivery agent. We 
tested, PANC-1 to understand the activity of gemcitabine had been retained in the 
nanoconjugated form. The percentage (%) of live PDAC cells (PANC-1 cell line) were 
evaluated by flow cytometry after exposure of 48 h with PEG-AuNPs 
[34]
  as control , GEM 
ION PEG-AuNPs  and HIV Tat-1 GEM ION  PEG-AuNPs  .  As described previously, PEG-
COOH do not impact on the toxicity of the final nanocarrier 
[4]
. It is evident from the Figures 
S3 in Supplementary Information that HIV Tat-1 GEM ION-PEG-AuNPs substantially 
inhibited proliferation of pancreatic cancer cells  at lowest concentrations (from 1.7µM to 
0.085 µM). Otherwise, the inhibition of proliferation of PANC-1 cells   by GEM ION-PEG-
AuNPs was more evident at highest concentration (from 3.4 µM to 17 µM). This original 
biological behavior, is probably due to a chemical and steric arrangement of peptide onto 
GEM PEGylated gold nanoparticles that induce a different biological activity at lower 
concentrations. These data clearly suggest an original behaviour of HIV Tat-1 and 
gemcitabine in the nano-conjugated form retains its specific targeting ability expressing 
cancer cells in vitro. All nanoparticles were free endotoxin and suitable for further 
nanomedicine applications. 
 
Photothermal heating : 
A photothermal effect occurs when a metallic nanoparticles converts the absorbed photon 
onto heat. This conversion is a consequence of a plasmonic relaxation of the nanoparticle 
localized plasmons after a photon excitation 
[35]
.This effect depending on nanoparticle nature, 
shape and size, has been widely exploited to destroy cancer cells 
[36]
, drug delivery and 
photodynamic therapy because of their ability to selectively drive temperature-sensitive 
chemical reactions 
[37]
. For an ideal PTT nanovector, several conditions should be fulfilled, 
including suitable size and shape for a NIR region illumination, but also a low cytotoxicity to 
healthy tissues 
[38]
. 
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Recently, highly crystalline and monodisperse NPs have demonstrated excellent properties 
that can be applied to areas such as drug delivery, cell separation and hyperthermia
[39]
 . To 
evaluate the photothermal effect of our NPs in object (GEM ION PEG-AuNPs, HIV-1 Tat 
GEM ION PEG-AuNPs, PEG-AuNPs (i.e.control), we investigate the temperature changes 
under 808 nm and 1 W.cm
2
 laser irradiation after the 3 steps of NPS synthesis (Figure 5a). 
The temperature elevation rose rapidly after 5 minutes in the three solutions. The temperature 
increase was stabilized after 15 minutes and reached the value of +8°C for  PEG AuNPs 
(control), +35°C for GEM ION PEG-AuNPs   and +27°C for HIV-TAT GEM ION  PEG-
AuNPs   , while the temperature elevation of the buffer increased only by 1°C. With a LSPR 
peak close to the 808 nm laser irradiation in the case of GEM ION PEG-AuNPs  (50 nm) and 
HIV-TAT GEM ION  PEG-AuNPs (63 nm), the absorption of photons is rapidly converted to 
heat, which results in a fast increase of temperature compared to PEG AuNPs  (7.5 nm) and 
which is not possible in the buffer solution. The temperature elevation was measured after 15 
minutes irradiation by varying the laser power from 0.12 to 3 W after the 3 steps of NPs 
synthesis (Figure 5b). We noticed that the temperature elevation increased linearly until 
1W.cm
2
 irradiation power. After this irradiation level, the temperature seemed to be 
increasing slowly between 1W and 3W laser power. We attribute this phenomenon to a 
maximum conversion of the optical energy to heat by NPS until 1W laser power. Further, this 
conversion becomes less efficient and the temperature increase was measured to +52°C for 
GEM ION PEG-AuNPs and +47°C for HIV-1 TAT GEM ION PEG-AuNPs  at 3W 
irradiation power. While for PEG-Au NPs, the temperature elevation was lower +32°C and 
negligible for the buffer solution +4°C. By increasing the laser power and exposition time, we 
observed that the temperature increase of HIV-1 TAT GEM ION PEG-AuNPs was slightly 
lower than GEM ION PEG-AuNPs   with a maximum temperature difference of 5°C, while 
the rate of the temperature rise was approximately the same. These last results showed that the 
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energy transfer from the NPs to the surrounding media was weakly affected by the presence 
of the HIV-1 TAT molecules.  
 
3. CONCLUSIONS 
In the present article three objectives were carried out: first, we designed and synthesized 
GEM based gold nanovector  (GEM ION PEG AuNPs)    using a “simple” method implying 
hybrid NPs with biocompatible capping materials (diacide PEG). Second, we combined an 
original active targeting onto GEM ION PEG AuNPs throught HIV-1 Tat peptide 
functionalization in order to , investigated the efficacy of HIV-1 Tat GEM ION PEG AuNPs  , 
before and after internalization in PDAC cells . Third, we suggest a preliminary photothermal 
heating study of these nanostructure in order to develop a multitask nanovector with a  highly 
effective cancer therapy. These findings and speculations main headlines the potential of the 
chemical  approach to study GEM–gold interactions in relation to drug delivery and drug 
targeting activity. Further studies are still envisaged, focused on assessing the in vivo 
assessment toxicity, pharmacokinetics and dynamics on relevant pancreatic-cancer model. 
 
4. EXPERIMENTAL SECTION  
Materials and methods 
All chemicals were reagent grade or higher and were used as received unless otherwise 
specified. Tetrachloroauric acid (HAuCl4*H2O), sodium borohydride (NaBH4), N-
hydroxysuccinimide (NHS), 1-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride 
(EDC), dicarboxylic PolyEthylene Glycol (PEG)-600 (PEG), phosphate buffered saline (PBS, 
0.1 M, pH  from 4 to 13), Gemcitabine (98%), HIV-1 Tat peptide were purchased from Sigma 
Aldrich. 
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Synthesis of GEM ION-PEG-AuNPs 
The main steps of synthesis of GEM ION-PEG-AuNPs colloids are described in Scheme 1. 
10 ml HAuCl4 aqueous solution (2.5×10
-4 
M) was added to 250 µl of dicarboxylic 
PEG  .mixed by magnetic stirring for 20 min at room temperature. After 20 min, 2 ml of GEM 
solution (1.72*10-4M) was added under magnetic stirring for 1h at room temperature.  Finally, 
1.2 ml of aqueous 0.01 M NaBH4 was added at once. The formation of the GEM IN-PEG-
AuNPs was observed as an instantaneous colour change of the solution from pale yellow to 
blu-violet after addition of the reducing agent. Products of each synthetic step were stored at 
27-29 °C and characterized by UV-Vis spectroscopy, Transmission Electron Microscopy, and 
Raman spectroscopy. The “as-prepared” GEM IN-PEG-AuNPs solution was centrifuged at 
11,000 rpm for 15 min for three times; then, the supernatant was discarded. This was repeated 
twice to remove excess of not-conjugated dicarboxylic PEG. 
 
Synthesis of PEG-AuNPs  
Synthetic procedures were carried out as previously described 
[4b]
. 
 
Stability of GEM ION-PEG-AuNPs as function of pH 
The stability of nanoparticles was detected by UV VIS. GEM ION-PEG-AuNPs nanoparticles 
were dissolved in PBS solution 0.1M at different pH (pH 5, 7, 8, 9, 12, 13) during 18h 
(Figure S1 Supporting Informations).  
 
HIV-1 Tat Peptide immobilization onto GEM ION-PEG-AuNPs 
 
The binding of HIV-1 Tat peptide  onto GEM ION-PEG-AuNPs surface was performed at pH 
9.0 in PBS. Briefly, 20 μl of EDC/NHS (80/20 w/w ratio) aqueous solution was added into 5 
ml of GEM ION-PEG-AuNPs dispersion. After 2 h, 50 µL (0.5 ng/ml) of HIV-1 Tat in PBS 
was added in 2 ml of the reaction mixture and stirred for 3 h at room temperature. The 
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obtained HIV-1 Tat -GEM ION-PEG-AuNPs were centrifuged two times at 9,000 rpm for 10 
min to remove excess of not-conjugated HIV-1 Tat and dried under nitrogen.  
 
Physico-chemical characterization  
 
All the measurements were performed in triplicate in order to validate the reproducibility of 
the synthetic and analytical procedures. All the measurements were carried out as previously 
described 
[4b, 13b]
. 
UV/Vis measurements 
Absorption spectra were recorded using a Perkin Elmer Lambda UV/Vis 950 
spectrophotometer in plastic cuvettes with an optical path of 10 mm. The wavelength range 
was 200–900 nm 
 
Transmission Electron Microscopy (TEM) 
All microscopy analysis were realized as previously described 
[4b, 13b]
.  
Raman Spectroscopy The Raman experiments have been performed on an Xplora 
spectrometer (Horiba Scientifics-France). The Raman spectra have been recorded using an 
excitation wavelength of 785 nm (diode laser) at room temperature. For measurements in 
solution, a macro-objective with a focal length of 40 mm (NA = 0.18) was used in 
backscattering configuration. The achieved spectral resolution is close to 2 cm
-1
. 
 
Dynamic light scattering (DLS): The size measurements were performed using a Zetasizer 
Nano ZS (Malvern Instruments, Malvern, UK) equipped with a He-Ne laser (633 nm, fixed 
scattering angle of 173°) at room temperature. 
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Zeta potential measurements: All measurements were carried out as previously described 
[4b]
. 
Drugs loading efficiency: The amount of the drug (GEM ) incorporated onto GEM ION-
PEG-AuNPs  was  measured by UV-Vis absorption spectroscopy. Absorption at 268 nm was 
used to extrapolate GEM concentrations based on a calibration curve (Figure S2 in the 
Supporting Information). The Drug loading efficiency was calculated as follows (Equation 
1): 
                          
     
  
        Equation 1 
Where C1 is the initial drug content and C2 is the amount of free GEM in the filtrate after 
separation of the nanoparticles by ultrafiltration with an Ultrafree MC centrifugal filter units, 
(30,000 NMWL, Millipore, USA). 
 
Drug release from AuNPs:  GEM releases was evaluated at physiological temperature 
(37°C). Drug-loaded AuNPs was dispersed at concentration of 1.8×10
12 
particles/ml in 1.3 ml 
PBS and performed by dialysis as previously described 
[13b]
. The concentration of drug 
released from AuNPs was expressed as a percentage of the total drug concentration present in 
the sample (Equation 2) and plotted as a function of time. 
               
                           
                        
    Equation 2 
 
Endotoxin content in Drug-gold nanoparticles: 
As routine quality control of the materials prior to biological testing, the Pierce LAL 
Cromogenic Endotoxin Quantitation kit (Thermoscientific, France) was used to determine the 
LPS contamination in Drug-gold nanoparticles (GEM ION-PEG-AuNPs) before and after 
conjugation with HIV-1 Tat peptide as described previously
[4a]
. Results, are reported in Table 
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1 as average (ntest =2) ±standard deviation. Endotoxin contamination results were kept into 
account when defining the type of cytotoxic endpoint to be examined. 
 
Sample Endotoxin Units ( EU/ml) 
PEG-AuNPs ( control)  ND 
HIV-1 Tat GEM ION PEG-AuNPs >1 
GEM ION-PEG-AuNPs ND 
HIV-1 Tat peptide >1 
 
Table 1. Endotoxin units detected by means of the LAL Chromogenic Endotoxin Quantitation 
kit (ND = not detectable; >1= above detection limit of the assay). 
 
 
 
Measurement of photothermal heating: 
We irradiated 1mL of 1 nM nanoparticles in aqueous solution inside a quartz cuvette with a 
808 nm continuous laser (FocusLight, China) at different power densities (0.12 to 3 W.cm
-2
) 
for 15 minutes at room temperature (23 °C). The temperature of colloids was recorded at 0.5 
minute intervals using a thermocouple probe (Hanna Instruments, USA) with an accuracy of 
0.1 °C. The sample volume, the nanoparticles concentration and the spot size (1 cm
2
) were 
remained constant and the temperature increase was measured as a function of the laser power 
and time. 
In vitro biological activity of GEM IN-PEG-AuNPs and  HIV-1 Tat-GEM IN-PEG-
AuNPs 
Cell culture 
PANC-1 cells, a human pancreatic carcinoma cell line, were obtained from the American 
Tissue Culture Collection (ATCC). PANC-1 cells were cultured in DMEM (Gibco, Bio-
Sciences Ltd, Ireland) under previously reported
[4a]
.  
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Cell treatment 
PANC-1 cells were exposed to a series of GEM ION-PEG-AuNPs , HIV-1 Tat -GEM IN-
PEG-AuNPs  and PEG-AuNPs (control) dilutions in complete media (DMEM+10% FBS) 
(concentrations ranging from 0 to 17µM of GEM ION -PEG-AuNPs and  HIV-1 Tat GEM IN 
-PEG-AuNPs)  for 48 h in 12 well plates as the procedure previously described
[4a]
.Cells were 
seeded at a density of 5×10
3
 cells/well, 100 μL/well in a 96-well plate. After 48 hours, cells 
were washed with PBS and incubated with CCK8 dilutions in complete media (100 μL/well) 
for 4h at 37°Cand 5% CO2and OD450 were analysized using an Microplate Reader. 
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Figures and scheme 
 
Scheme 1. Schematic representation of the synthesis of GEM ION-PEG-AuNPs via polymer 
reduction (Please note that drawings are not in scale and are not intended to be representative 
of the full samples composition).  
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Figure 1. TEM images of PEG-AuNPs (A) and GEM ION PEG-AuNPs (B); (C) normalized 
UV-Vis absorption and (D) Raman spectra GEM ION PEG-AuNPs products compared to free 
GEM as control. (A-B) Scale bars:  20 nm. (D) Raman spectra. Experimental conditions: λexc 
= 785 nm; laser power 20 mW; accumulation time 180s.  
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Figure 2: A) Drug release percentage (%) of GEM ION PEG-AuNPs time in PBS (37 °C) at 
pH = 4.0 or at pH = 7.0. B) Schematic diagram of GEM release under pH conditions. 
 
 
 
 
Figure 3: TEM images of PEG-AuNPs (A) and GEM ION PEG-AuNPs (B); (A) normalized 
UV-Vis of GEM ION PEG-AuNPs before ( red line) and after ( blacj line) traitment under 
ionic strength conditions . (B) TEM images   of GEM ION PEG-AuNPs ( low and high 
magnification) in NaCl (0.9%; 50 µl; 48h) 
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Scheme 2. Schematic representation of HIV-1 Tat protein bio-conjugating onto GEM IN-
PEG-AuNPs surface   (Please note that drawings are not in scale and are not intended as 
representative of the full samples composition). 
 
 
 
 
Figure 4: (A) Extinction spectra of GEM ION PEG-AuNPs before (blue line) and after 
conjugation to HIV-1 tat peptide (black line)  
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Figure 5: (a) Time-dependant temperature elevation of  PEG-Au NPs, GEM ION PEG-
AuNPs  , HIV-1 Tat GEM ION PEG-AuNPs and buffer under 808 nm laser (1 W.cm
-2
). (b) 
Laser power effect on photothermal heating on NPS compared to the control solution (buffer 
alone) after 15 minutes irradiation time. The temperature elevation of NPS is higher than the 
minimum temperature required for cell killing in PTT (+4°C).   
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ADDITIONAL SCHEMES 
 
 
 
 
 
Scheme S1. Chemical structure of Gemcitabine (GEM). Rings and chemical groups are 
identified with number; this nomenclature is used for Raman band assignments. A blue ring is 
associated to site of complexation with gold ions; red and green rings are associated to ionic 
interactions. 
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ADDITIONAL FIGURES 
 
 
 
 
Figure S1. UV vis spectra of GEM ION-PEG-AuNPs in buffer solutions at different pH  
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Figure S2 : UV-Vis absorption spectra of GEM at increasing known concentrations. (b) 
calibration curve extrapolated from such measurements. The amount of GEM molecules 
grafted onto GEM ION-PEG-AuNPs, was estimated based on this curve. 
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Figure S3: Proliferation PANC-1 cells of GEM ION-PEG-AuNPs, HIV-TAT GEM ION-
PEG-AuNPs,   and PEG-AuNPs (i.e. control) during 48h h at different concentrations.  
 
 
 
 
 
 
 
